PET Imaging in Bladder Cancer: An Update and Future Direction

Zhang-Yin, Jules; Girard, Antoine; Marchal, E.; Lebrét, Thierry; Seban, Marie Homo; Uhl, Marine; Bertaux, M.

doi:10.3390/ph16040606

Pharmaceuticals

2023

DOI: 10.3390/ph16040606

|View full text |Cite

PET Imaging in Bladder Cancer: An Update and Future Direction

Jules Zhang-Yin

Antoine Girard

E. Marchal

et al.

Abstract: Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [18F] 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of bladder cancer patients, especially for staging and follow-up; treatment … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

FDG PET/CT in Staging and Response Evaluation of Primary Urothelial Carcinoma of the Urethra

Zhang,

Dong,

Wang

2024

Clin Nucl Med

View full text Add to dashboard Cite

Primary urethral urothelial carcinoma is a rare aggressive tumor with a high propensity for local invasion and regional and distal metastases. We describe the usefulness of FDG PET/CT in management of a patient with primary urethral urothelial carcinoma. FDG PET/CT at initial staging showed FDG-avid primary tumor and lymph node metastasis of the left groin, and mild or no activity of the lung metastases due to small size. FDG PET/CT after 4 cycles of chemotherapy showed progression of the primary tumor and lung metastases, partial response of the left inguinal lymphadenopathy, and multiple new sites of FDG-avid metastases.

show abstract

FDG PET/CT in Staging and Response Evaluation of Primary Urothelial Carcinoma of the Urethra

Zhang,

Dong,

Wang

2024

Clin Nucl Med

View full text Add to dashboard Cite

show abstract

Conventional and innovative imaging modalities in bladder cancer: Techniques and applications

Masino,

Eusebi,

Muscatella

et al. 2024

Digital Diagnostics

View full text Add to dashboard Cite

This narrative review aims to describe the current status of imaging in the evaluation of Bladder Cancer, considering conventional technologies such as Ultrasound, Computed Tomography Urography, and Magnetic Resonance Imaging as well as novel technologies such as Contrast-Enhanced Ultrasound and Dual Energy Computed Tomography. The article is organized by first presenting an introduction to both the anatomy of the bladder in order to understand the normal appearance on imaging, and both the main features of bladder cancer with a reference to epidemiology, clinic, classification, and treatment. Subsequently, the role of imaging is discussed with an explanation of the technique and the applications in Bladder Cancer assessment for each modality. Imaging plays a critical role in the detection and staging of Bladder Cancer. In particular, MRI is acquiring an increasing role, since it makes it possible to distinguish between MIBC and NMIBC using the VI-RADS score system, at the side of conventional technologies like CTU and the US. To ensure the right approach to the oncological patient CEUS and DECT represent emerging modalities with specific advantages.

show abstract

The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature

Santarelli,

Rosati,

Canale

et al. 2024

Life

View full text Add to dashboard Cite

Contrast-enhanced ultrasound (CEUS) is an advanced imaging technique that integrates conventional US with the intravenous injection of specific US contrast agents (UCAs), combining the non-invasiveness of US with the higher accuracy of contrast-enhanced imaging. In contrast with magnetic resonance imaging (MRI), computed tomography (CT) and cystoscopy, CEUS has few contraindications, and UCAs are non-nephrotoxic agents that can be safely used in patients with kidney failure. CEUS is a well-established method for the detection of liver lesions and for echocardiography, and its indications are expanding. The updated 2018 WFUMB-EFSUMB guidelines have added the urinary bladder under non-hepatic applications of CEUS. The technique is able to distinguish between benign tissue, such as clots or hematoma, and malignant lesions by perfusing the mass with contrast agent. Thanks to the different perfusion rates of the various layers of the bladder wall, CEUS is also able to predict tumor invasion depth and stage. Despite that, current urological guidelines do not include CEUS as a plausible imaging technique for bladder urothelial carcinoma. The main reason for this omission might be the presence of scarce randomized evidence and the absence of large validated series. In this review, we describe the rationale behind the use of CEUS in bladder cancer and the added value of this imaging technique in the detection and staging of bladder lesions. In addition, we researched the available literature on the topic and then described the results of randomized clinical trials and a meta-analysis investigating the accuracy of CEUS in bladder cancer diagnosis and staging. The reported studies show that CEUS is a highly accurate diagnostic and staging tool for BC, reaching levels of specificity and sensitivity in differentiating between Ta-T1, or low-grade BC, and T2, or high-grade BC, that are comparable to those shown by the reference standard methods. Nonetheless, several limitations were found and are highlighted in this review. The aim of this study is to further validate and promote the use of CEUS as a quick, economic and effective diagnostic tool for this high-impact disease.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

PET Imaging in Bladder Cancer: An Update and Future Direction

Cited by 3 publications

References 85 publications

FDG PET/CT in Staging and Response Evaluation of Primary Urothelial Carcinoma of the Urethra

FDG PET/CT in Staging and Response Evaluation of Primary Urothelial Carcinoma of the Urethra

Conventional and innovative imaging modalities in bladder cancer: Techniques and applications

The Current Role of Contrast-Enhanced Ultrasound (CEUS) in the Diagnosis and Staging of Bladder Cancer: A Review of the Available Literature

Contact Info

Product

Resources

About